Business
oi-Renu Baliyan
Small cap company operating in pharmaceuticals sector, Gujarat Themis Biosyn Ltd on Saturday declared its Q4 FY23 results. The board of directors of the company recommended dividend and stock split in the ratio of 1:5. The shares of the company gave 105% return in last 1-year only. Check details below:

Gujarat Themis Biosyn Declares Dividend: According to the exchange filing of the company, “Recommended dividend for Financial Year ended 31.03.2023 of Rs.1/- l.e. @ 20% per equity share having face value of Rs.5/- , aggregating to Rs. 1,45,28,702. The payment is subject to the approval of shareholders af the ensuing AGM.”
Gujarat Themis Biosyn Announces Stock Split: As per the BSE filing of the company, “The Board considered the proposal for sub-division of 1 equity share of the Company having face value of Rs.5/- each info 5 (five) equity shares having face value of Rs.1/- each, subject to regulatory/statutory approvals as may be required and the approval of the shareholders of the Company for the financial year 2023-24.”
Gujarat Themis Biosyn Stock Performance & Return: Last trading price of Gujarat Themis Biosyn is Rs 792.85 per share on BSE. Its 52-week high price is Rs 921.05 per share and 52-week low price is Rs 376.10 per share, respectively. The company’s market capitalisation is Rs 1,151.91 crore.
The stock rallied 29% in last 3-months, 105% return in last 1-year, 186% return in last 2-years, 346% return in last 3-years, and 1877% return in last 5-years.
About Gujarat Themis Biosyn: Gujarat Themis Biosyn Limited was incorporated in 1981 as a joint sector company with GIIC Ltd. and Chemosyn (P) Ltd. It commenced production in August 1985. It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd.
Disclaimer:The small cap company declared stock split and dividend. Greynium Information Technologies and the author are not liable for any losses caused as a result of decisions based on the article. Goodreturns.in advises users to check with certified experts before taking any investment decision.
Story first published: Saturday, May 13, 2023, 23:04 [IST]